GlassScriptPhysician profile
Michelle Auld
NPI 1336699941
$4,128.27
in general payments reported to CMS, 2019-2025
30 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,047 · 2023: $1,177 · 2024: $1,180 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.78 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $601.55 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbott Laboratories | $306.14 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $256.12 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $253.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $253.06 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $138.68 | 2022-2024 | Evenity, Otezla, Repatha |
| Merz North America, INC. | $127.70 | 2025 | |
| Antares Pharma, INC. | $127.07 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Galderma Laboratories, L.P. | $125.39 | 2025 | |
| Astellas Pharma US INC | $86.37 | 2022-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.72 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $78.26 | 2022-2023 | Glassia |
| Axsome Therapeutics, INC. | $65.53 | 2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $56.40 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $53.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.75 | 2022-2025 | Spravato |
| Lilly USA, LLC | $26.35 | 2023 | Jardiance, Lyumjev, Mounjaro |
| Novo Nordisk INC | $25.24 | 2022-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.87 | 2022 | |
| The Binding Site INC. | $19.84 | 2023 | Freelite |
| Almatica Pharma LLC | $19.65 | 2024 | Loreev Xr |
| Corium, LLC | $19.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2023 | |
| Dexcom, INC. | $17.29 | 2022 | |
| Seqirus USA INC | $14.81 | 2022 | |
| Esperion Therapeutics, INC. | $14.04 | 2022 | |
| Sanofi Pasteur INC. | $13.50 | 2023 | |
| Genentech USA, INC. | $11.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Auld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.